These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 3915010)
21. A case series of 48 patients treated with thalidomide. Doherty SD; Hsu S J Drugs Dermatol; 2008 Aug; 7(8):769-73. PubMed ID: 18720694 [TBL] [Abstract][Full Text] [Related]
22. Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders. Ladizinski B; Shannon EJ; Sanchez MR; Levis WR J Drugs Dermatol; 2010 Jul; 9(7):814-26. PubMed ID: 20677538 [TBL] [Abstract][Full Text] [Related]
23. Thalidomide and its dermatologic uses. Paghdal KV; Schwartz R Acta Dermatovenerol Croat; 2007; 15(1):39-44. PubMed ID: 17433179 [TBL] [Abstract][Full Text] [Related]
24. [Thalidomide: an eclectic medication in dermatology]. Proença NG Rev Paul Med; 1989; 107(1):41-6. PubMed ID: 2694291 [TBL] [Abstract][Full Text] [Related]
29. Ovarian failure with thalidomide treatment in complex aphthosis: comment on the concise communication by Ordi et al. Gompel A; Frances C; Piette JC; Blanc AS; Cordoliani F; Piette AM Arthritis Rheum; 1999 Oct; 42(10):2259-60. PubMed ID: 10524707 [No Abstract] [Full Text] [Related]
30. Poststeroid nodular panniculitis and the erythema nodosum of leprosy. Browne SG Dermatol Int; 1965; 4(4):215-8. PubMed ID: 5879055 [No Abstract] [Full Text] [Related]
31. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. Tseng S; Pak G; Washenik K; Pomeranz MK; Shupack JL J Am Acad Dermatol; 1996 Dec; 35(6):969-79. PubMed ID: 8959957 [TBL] [Abstract][Full Text] [Related]
32. Thalidomide enhances defective monocyte function in lepromatous leprosy. Nielsen H; Bennike T Lancet; 1984 Jul; 2(8394):98-9. PubMed ID: 6146029 [No Abstract] [Full Text] [Related]
33. [Supidimide, a non-teratogenic thalidomide analog for the treatment of leprosy reaction?]. Sheskin J; Mückter H; Frankus E Hautarzt; 1983 Apr; 34(4):168-70. PubMed ID: 6853166 [No Abstract] [Full Text] [Related]
34. [Therapy of skin- and venereal diseases. Review of the literature 1969]. Walther H Dtsch Med J; 1970 Jun; 21(12):870-6 passim. PubMed ID: 4259633 [No Abstract] [Full Text] [Related]
35. [Our experience in the therapy of leprous reactions with thalidomide]. Baccaredda-Boy A; Bertamino R Minerva Dermatol; 1968 Aug; 43(8):357-9. PubMed ID: 5745776 [No Abstract] [Full Text] [Related]
36. No role for thalidomide in the treatment of leprosy. Crawford CL J Infect Dis; 2006 Jun; 193(12):1743-4; author reply 1744-5. PubMed ID: 16703522 [No Abstract] [Full Text] [Related]
37. Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions. Barnhill RL; McDougall AC J Am Acad Dermatol; 1982 Sep; 7(3):317-23. PubMed ID: 7130490 [TBL] [Abstract][Full Text] [Related]
38. [Rondomycin and TAO in dermatological diseases and their complications]. Roszczynialska M; Pawlowski A Przegl Dermatol; 1970; 57(1):79-83. PubMed ID: 5417329 [No Abstract] [Full Text] [Related]
39. The effects of thalidomide on leprosy reaction. Languillon J Int J Lepr Other Mycobact Dis; 1971; 39(2):590-2. PubMed ID: 4948094 [No Abstract] [Full Text] [Related]
40. Thalidomide in dermatology. New indications for an old drug. Calderon P; Anzilotti M; Phelps R Int J Dermatol; 1997 Dec; 36(12):881-7. PubMed ID: 9466191 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]